No abstract

Objectives: To study the prevalence of fluoroquinolone-resistant and extended spectrum β-lactamase-producing isolates at Phramongkutklao Hospital, Thailand, and to identify the risk factors predicting the carriage of these organisms. Methods: Menundergoing transrectal ultrasound-guided prostate biopsy were prospectively enrolled between February and October2015. Rectal swab culture was obtained before antimicrobial prophylaxis andprostate biopsy. Univariate and multivariate analyses were performed to identify the independent risk factors associated with antimicrobial-resistant flora. Results: In total, 99 patients underwent biopsy, of whom 38 (38.4%) had antimicrobial-resistant rectal flora,with 26 (26.3%) having fluoroquinolone-resistant rectal flora and12 (12.1%) having both fluoroquinolone-resistant rectal flora and extended spectrum β-lactamase.The incidence of postbiopsy infections was 6.1%. The use of antibiotics in the past 6 months was found in 23.7% of the resistant group vs.6.6% of the sensitive group(odds ratio = 4.86,p= 0.030),with the previous biopsy history being 31.6% and14.8% (odds ratio = 3.17, p= 0.036),respectively. Postbiopsy infectionsoccurred in13.2% and1% (odds ratio = 10.69,p= 0.045) of patients in the resistant and sensitive groups, respectively. Conclusions: The prevalence offluoroquinolone-resistant rectal flora increased in patients undergoing transrectal prostate biopsyat Phramongkutklao Hospital, Thailand. A history of antibiotics in the past 6 months, previous biopsy, andpostbiopsy infections were associated with antimicrobialresistance. Culture-directed prophylaxis antibiotics may reduce postbiopsy infections after transrectal prostate biopsy.

Background: Renal cell carcinoma (RCC) is the most common kidney cancer in adults. Computed Tomography (CT) with contrast study is used to diagnose RCC. The enhancement in the nephrogenic phase more than 15 Hounsfield units (HU) is suspected of RCCs. However, this threshold HU shows 15-20% false positive results for RCCs. Objectives: This study aimed to determine RCC enhancement in CT that was below the standard threshold and to analyze the attenuation range of RCCs in noncontrast CT. Methods: Patients with pathological RCC and undergoing CT with contrast study were retrospectively reviewed. An average of attenuation values of three regions of interest (ROI) were measured in noncontrast and nephrogenic phases, by avoiding foci of calcification and peritumoral region. ROI values were calculated for enhancement and range of attenuation values in the noncontrast CT. Results: A total of 152 pathologically RCCs were included in the study. Mean ± SD attenuation values were 32.54 ± 8.02 HU (range 13.3-57.23 HU) and 71.26 ± 33.1 HU (range 16.87-202.8 HU) for noncontrast and contrast CT, respectively. Thirty-one (20.4%) of RCCs did not reach 15 HU enhancement. Using multivariate analysis, significant differences among subtypes (p<0.001) and renal mass less than 7 cm (p<0.001) were observed. In noncontrast CT, using a range of 20-60 HU, 129 (84.9%) RCCs were entirely within this range. To improve the accuracy of RCC diagnosis, the combined use of both non-contrast attenuation group (<20 HU and >20 HU) and enhancement >15 HU could increase the accuracy to 96.7%. Conclusion: One-fifth of RCCs did not reach the standard enhancement threshold that were mostly found in nonclear cell subtype. Especially, when the mass was larger than 7 cm or involved nonclear cell RCCs, the enhancement threshold >15 HU must be carefully used for diagnosis. Using a noncontrast phase regardless HU combined with enhancement >15 HU could improve the accuracy of RCC diagnosis.

No abstract